Infectious Diseases

Leading the Charge Against Infectious Diseases
Schedule a Call

Leading Infectious Disease Research

hVIVO provides unparalleled scientific capability in respiratory infectious disease research, underpinned by decades of virology expertise and a comprehensive suite of validated Human Challenge Models across influenza, RSV, hMPV, HRV, COVID19 and other priority pathogens. Supported by BSL2 and BSL3 facilities, inhouse model development, manufacturing and integrated early phase clinical and laboratory operations, our platform enables precise characterisation of host–pathogen dynamics and high resolution evaluation of novel vaccines and therapeutics.

World leader in Human Challenge Trials with models for influenza, RSV, hMPV, HRV, COVID‑19, Influenza, and Malaria   

Expanded capabilities beyond respiratory diseases to pathogens including Dengue, Zika, Norovirus, and Bordetella pertussis.

State‑of‑the‑art Human Challenge Unit facility with Containment Level 3 (BSL‑3) and onsite BSL‑3 labs. 

Over 80+ Human Challenge Studies delivered, including the first SARS‑CoV‑2 challenge study, and the only commercially available  fully characterised models for hMPV,  RSV-B and Omicron

Infectious Disease Capabilities

Pathogen & Model Development or Selection 

Discover our available models and how to develop a customised model

virus-image (2)

 

Facilities & Infrastructure

Including BSL2 & BSL3 

hVIVO_Vaccine_Research2

 

Multifaceted Infectious Disease Laboratory

Including, Molecular, Immunology, Virology  and Bacteria 

hVIVO_Lab_Services_ELISpot-1

 

Human Challenge

World-leaders in human challenge studies

A Catchpole Presenting to Audience

 

Research & Articles

View all Resources
BlogHuman challenge trialsInfectious diseasesRespiratory viruses

From RSV to hMPV: Building the Next Generation of Respiratory Challenge Models

Andrew Catchpole
Andrew Catchpole Chief Scientific Officer
10 Apr 2026 7 min read
View
BlogLaboratoryHuman challenge trialsInfectious diseasesRespiratory viruses

Controlled Human Infection Model's (CHIM) in your backpack: how Human Challenge Trials support regulatory approval of travel vaccines

Andrew Catchpole
Andrew Catchpole Chief Scientific Officer
10 Apr 2026 5 min read
View
BlogHuman challenge trialsTrial designInfectious diseasesRespiratory viruses

Unravelling the hMPV Surge: From Media Attention to Vaccine Development

Andrew Catchpole
Andrew Catchpole Chief Scientific Officer
10 Apr 2026 6 min read
View

FAQ

Get in touch with us

 hVIVO’s scientific leadership is anchored in respiratory infectious diseases, supported by decades of virology expertise and a broad portfolio of validated Human Challenge Models—including influenza, RSV, hMPV, HRV, COVID19 and other priority pathogens. 

 hVIVO operates advanced Containment Level 2 and Level 3 (BSL2 / BSL3) clinical and laboratory facilities, including a stateoftheart Human Challenge Unit and onsite BSL3 laboratories.
These facilities are complemented by a multifaceted infectious disease laboratory covering molecular, bacteriology, immunology and virology platforms.  
 hVIVO delivers comprehensive early phase development support, from pathogen/model selection and protocol design through to full regulatory alignment and execution of Human Challenge Studies.
This integrated clinical laboratory ecosystem enables high resolution evaluation of host–pathogen dynamics and accelerates data generation for novel vaccines and therapeutics  

Accelerate Your Infectious Disease Programme

Contact us

Enquire now